HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance66% confidence

FDA TA — ANDA219413

Source: FDA

Why This Matters

Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for TEVA PHARMACEUTICALS, INC; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

Application ANDA219413. Sponsor: TEVA PHARMACEUTICALS, INC.. Submission status: TA. Submission type: ORIG. Review priority: STANDARD.

Supporting Context

Therapeutic area
Not specified
Sub-indication
General

Related signal: TEVA Pharmaceuticals submits ANDA219413 for FDA review

Source

View source document

Related Signal

Open signal — TEVA Pharmaceuticals submits ANDA219413 for FDA review
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.